NanoViricides Net Income Over Time
| NNVC Stock | USD 1.00 0.08 7.41% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out NanoViricides Performance and NanoViricides Correlation. NanoViricides | Build AI portfolio with NanoViricides Stock |
Will Biotechnology sector continue expanding? Could NanoViricides diversify its offerings? Factors like these will boost the valuation of NanoViricides. Anticipated expansion of NanoViricides directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every NanoViricides data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding NanoViricides requires distinguishing between market price and book value, where the latter reflects NanoViricides's accounting equity. The concept of intrinsic value—what NanoViricides' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push NanoViricides' price substantially above or below its fundamental value.
It's important to distinguish between NanoViricides' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding NanoViricides should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, NanoViricides' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare NanoViricides and related stocks such as Verrica Pharmaceuticals, Jasper Therapeutics, and SAB Biotherapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VRCA | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (4.5 M) | (20.6 M) | (27.9 M) | (45.5 M) | (35.1 M) | (24.5 M) | (67 M) | (76.6 M) | (68.9 M) | (65.5 M) |
| JSPR | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (31.7 M) | (30.6 M) | (37.7 M) | (64.5 M) | (71.3 M) | (64.1 M) | (67.3 M) |
| SABS | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | 20.1 M | (17.1 M) | (18.7 M) | (42.2 M) | (34.1 M) | (30.7 M) | (29.2 M) |
| GBIO | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (60.3 M) | (76.5 M) | (114.7 M) | (132.1 M) | (126.6 M) | (131.7 M) | (118.5 M) | (124.4 M) |
| EVAX | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | (11.2 M) | (15 M) | (24.5 M) | (23.2 M) | (22.1 M) | (10.6 M) | (9.5 M) | (10 M) |
| IGC | 91.9 K | (7.8 M) | (2.3 M) | (3 M) | (4.6 M) | (2.8 M) | (1.9 M) | (1.8 M) | (4.1 M) | (7.3 M) | (8.8 M) | (15 M) | (11.5 M) | (13 M) | (7.1 M) | (6.4 M) | (6.7 M) |
| QTTB | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (30 M) | (55.6 M) | (103.9 M) | (128.7 M) | (95.8 M) | (42.8 M) | (53.7 M) | (47.7 M) | (43 M) | (45.1 M) |
| MAIA | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.6 M) | (12.5 M) | (15.8 M) | (19.8 M) | (23.3 M) | (20.9 M) | (22 M) |
| ANTX | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (13.6 M) | (21.5 M) | (41.5 M) | (64.7 M) | (51.3 M) | (46.2 M) | (48.5 M) |
| TENX | (2.3 M) | (15.7 M) | (19.5 M) | (19.5 M) | (14.1 M) | (14.1 M) | (43.9 M) | (8.8 M) | (6.8 M) | (8.4 M) | (9.9 M) | (32.5 M) | (11 M) | (7.7 M) | (17.6 M) | (15.8 M) | (15 M) |
NanoViricides and related stocks such as Verrica Pharmaceuticals, Jasper Therapeutics, and SAB Biotherapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in NanoViricides financial statement analysis. It represents the amount of money remaining after all of NanoViricides operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| NanoViricides | NNVC |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 1 Controls Drive, |
| Exchange | NYSE MKT Exchange |
USD 1.0
Check out NanoViricides Performance and NanoViricides Correlation. For information on how to trade NanoViricides Stock refer to our How to Trade NanoViricides Stock guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
NanoViricides technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.